- Home
- DAVA vs TNYA Comparison
DAVA vs TNYA Comparison
Compare DAVA & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DAVA | TNYA |
|---|---|---|
| Founded | 2000 | 2016 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.1M | 171.4M |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | DAVA | TNYA |
|---|---|---|
| Price | $2.74 | $0.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 3 |
| Target Price | ★ $13.50 | $5.33 |
| AVG Volume (30 Days) | 369.6K | ★ 2.6M |
| Earning Date | 05-19-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.96 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.07 | N/A |
| P/E Ratio | $20.02 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.55 | $0.53 |
| 52 Week High | $15.20 | $2.35 |
Technical Indicators
Market Signals| Indicator | DAVA | TNYA |
|---|---|---|
| Relative Strength Index (RSI) | 40.64 | 60.90 |
| Support Level | $2.55 | $0.65 |
| Resistance Level | $3.02 | $0.94 |
| Average True Range (ATR) | 0.18 | 0.06 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 24.32 | 68.02 |
Price Performance
Historical ComparisonAbout DAVA Endava plc (each representing one)
Endava is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2006 in the UK, and it continues to generate the majority of revenue in the UK and Europe. Endava's client base is concentrated in the payments and financial services, technology, media, and telecom industries.
About TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.